Trajectories following Impella 5.5 support are associated with initial presentation acuity.

ABSTRACT:

Background

Impella 5.5 is a temporary left ventricular assist device utilized to support patients with cardiogenic shock and those undergoing high-risk cardiac interventions.

Methods

From October 2019 to January 2023, 226 patients received Impella 5.5 support at Cleveland Clinic main campus. Patients were stratified by Society for Cardiovascular Angiography and Interventions (SCAI) shock stages. Immediate post-Impella 5.5 trajectories were compared across groups. Trajectories were defined as mortality on Impella 5.5, transition to advanced heart failure therapies (durable left ventricular assist device/heart transplantation), or survival to Impella 5.5 removal without advanced therapies.

Results

Overall, 148 (65%) patients with cardiogenic shock and 78 (35%) undergoin

SUBMITTER: Maigrot JA 

PROVIDER: S-EPMC11687209 | biostudies-literature | 2025 Jan

REPOSITORIES: biostudies-literature